Serologic Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from PR Newswire. The AP news staff was not involved in its creation.

ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab)...

Pfizer-BioNTech’s COVID-19 vaccine effective and safe for use among cancer patients Researchers in Israel have conducted a study showing that the use of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine appears to be safe and effective among patients with cancer. “To our knowledge, this study is the first to prospectively characterize the serologic status, immunogenicity, and safety of the BNT162b2 vaccine in a cohort of patients with solid tumors who are receiving active anticancer therapies,” writes the team from the Rambam Health Care Campus, the Rappaport Faculty of Me...

July 8, 2021 • 11:11 am CDT (Precision Vaccinations) The JAMA Oncology published the results from a cohort study 'Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.' On July 8, 2021, this Original Investigation concluded by saying, 'In this cohort study of 223 cancer patients, the SARS-CoV-2 BNT162b2 vaccine (Pfizer-BioNTech, Comrinaty) appeared to be safe and achieve satisfactory serologic status.' 'There was a pronounced lag in antibody production compared with the rate in noncancer controls.' 'However, seroconversion occur...